Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Lonza Group Ltd ( (CH:LONN) ) just unveiled an update.
Lonza has announced several changes to its Board of Directors as part of a structured succession plan aimed at strengthening governance and strategic capabilities. The company has nominated Sami Atiya, a seasoned executive in healthcare, robotics, automation and AI from ABB and Siemens, as an independent board member and prospective member of the Strategy and Innovation Committee, subject to shareholder approval at the May 2026 AGM.
Claudia Süssmuth-Dyckerhoff, recently nominated as an independent member, will be appointed Vice-Chair and join the Remuneration as well as Strategy and Innovation Committees, while Marion Helmes will become Chair of the Audit and Compliance Committee. Long-serving directors Jürgen Steinemann and Barbara Richmond will step down after reaching their maximum tenure, and Roger Nitsch will not seek re-election to focus on entrepreneurial activities, marking a planned refresh of Lonza’s leadership that aligns board expertise with technological and industry shifts.
The most recent analyst rating on (CH:LONN) stock is a Buy with a CHF670.00 price target. To see the full list of analyst forecasts on Lonza Group Ltd stock, see the CH:LONN Stock Forecast page.
More about Lonza Group Ltd
Lonza Group is one of the world’s largest contract development and manufacturing organizations serving the healthcare industry. Operating across five continents with about 20,000 employees, it partners with pharma and biotech companies to transform innovations into commercial therapies, generating CHF 6.5 billion in sales and CHF 2.1 billion in CORE EBITDA in 2025.
Average Trading Volume: 148,545
Technical Sentiment Signal: Hold
Current Market Cap: CHF34.54B
Learn more about LONN stock on TipRanks’ Stock Analysis page.